PHASTAR announced that it has entered into a technology partnership with Medidata Solutions, Inc. PHASTAR will deploy several solutions from the Medidata Rave Clinical Cloud including Rave EDC, Coder, eCOA, and RTSM.
The adoption of the Medidata Rave Clinical Cloud comes as PHASTAR continues to grow its market share in data services. PHASTAR has expanded its Data Operations teams in Kenya and the UK to provide professional services, and, with the opening of its second U.S. office in Boston, its partnership with Medidata will further power its U.S. expansion.
PHASTAR understands that Medidata is an innovative partner that provides technology for servicing data studies, along with transformative and collaborative solutions to help PHASTAR support emerging techniques.
“We are excited to partner with PHASTAR in its mission to support the pharmaceutical and biotech sector in safely bringing new therapies and medical devices to patients,” said Glen de Vries, co-founder and president, Medidata. “Our unified platform will enable PHASTAR to design and conduct complex clinical trials, and turn large volumes of data into insights."
Andrew MacGarvey, Managing Director, PHASTAR, said, “I am pleased to expand our offering following the addition of the Medidata platform to our technology solutions. Our Data Operations team deliver excellent services across the world and Medidata will allow the team to service projects more efficiently as they work within the unified platform. Our new Data Sciences group is developing tools and techniques to help our customers maximise the data they collect. Medidata understand that the types of data collected during clinical trials are changing and the amount of data underpinning clinical research is increasing extremely quickly. We hope to work closely with their team as our customer needs evolve over the coming years.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.